The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Effects of Rosiglitazone and Metformin on Liver Fat Content, Hepatic Insulin Resistance, Insulin Clearance, and Gene Expression in Adipose Tissue in Patients With Type 2 Diabetes
Open accessAbstract
Both rosiglitazone and metformin increase hepatic insulin sensitivity, but their mechanism of action has not been compared in humans. The objective of this study was to compare the effects of rosiglitazone and metformin treatment on liver fat content, hepatic insulin sensitivity, insulin clearance, and gene expression in adipose tissue and serum adiponectin concentrations in type 2 diabetes. A total of 20 drug-naive patients with type 2 diabetes (age 48 +/- 3 years, fasting plasma glucose 152 +/- 9 mg/dl, BMI 30.6 +/- 0.8 kg/m2) were treated in a double-blind randomized fashion with either 8 mg rosiglitazone or 2 g metformin for 16 weeks. Both drugs similarly decreased HbA1c, insulin, and free fatty acid concentrations. Body weight decreased in the metformin (84 +/- 4 vs. 82 +/- 4 kg, P < 0.05) but not the rosiglitazone group. Liver fat (proton spectroscopy) was decreased with rosiglitazone by 51% (15 +/- 3 vs. 7 +/- 1%, 0 vs. 16 weeks, P = 0.003) but not by metformin (13 +/- 3 to 14 +/- 3%, NS). Rosiglitazone (16 +/- 2 vs. 20 +/- 1 ml.kg(-1).min(-1), P = 0.02) but not metformin increased insulin clearance by 20%. Hepatic insulin sensitivity in the basal state increased similarly in both groups. Insulin-stimulated glucose uptake increased significantly with rosiglitazone but not with metformin. Serum adiponectin concentrations increased by 123% with rosiglitazone but remained unchanged during metformin treatment. The decrease of serum adiponectin concentrations correlated with the decrease in liver fat (r = -0.74, P < 0.001). Rosiglitazone but not metformin significantly increased expression of peroxisome proliferator-activated receptor-gamma, adiponectin, and lipoprotein lipase in adipose tissue. In conclusion, rosiglitazone but not metformin decreases liver fat and increases insulin clearance. The decrease in liver fat by rosiglitazone is associated with an increase in serum adiponectin concentrations. Both agents increase hepatic insulin sensitivity, but only rosiglitazone increases peripheral glucose uptake.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Reductions in hepatic steatosis with both pioglitazone and rosig litazone ameliorate hepatic insulin resistance.134,135”
From Lipid-induced insulin resistance: unravelling the mechanism (2010) · cites this paper as [135]
In the citing paper
“We have previously shown that metformin does not change liver fat content.35”
From Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes. (2008) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621
Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., Mori, Y., Ide, T., Murakami, K., Tsuboyama-Kasaoka, N., et al. (2001) · Nature Medicine · doi:10.1038/90984 · Cited by 4,915
Maeda, N., Takahashi, M., Funahashi, T., Kihara, S., Nishizawa, H., Kishida, K., Nagaretani, H., Matsuda, M., Komuro, R., Ouchi, N., et al. (2001) · Diabetes · doi:10.2337/diabetes.50.9.2094 · Cited by 1,673
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus
Stumvoll, M., Nurjhan, N., Perriello, G., Dailey, G., & Gerich, J. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330903 · Cited by 1,148
Mechanism by which metformin reduces glucose production in type 2 diabetes.
Hundal, R. S., Krssak, M., Dufour, S., Laurent, D., Lebon, V, Chandramouli, V, Inzucchi, S. E., Schumann, W. C., Petersen, K. F., Landau, B. R., et al. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2063 · Cited by 1,052
Endogenous glucose production is inhibited by the adipose-derived protein Acrp30
Combs, T. P., Berg, A. H., Obici, S., Scherer, P. E., & Rossetti, L. (2001) · Journal of Clinical Investigation · doi:10.1172/jci14120 · Cited by 955
Minimization: A new method of assigning patients to treatment and control groups
Taves, D. R. (1974) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1974155443 · Cited by 891
Efficacy and Metabolic Effects of Metformin and Troglitazone in Type II Diabetes Mellitus
Inzucchi, S. E., Maggs, D. G., Spollett, G. R., Page, S. L., Rife, F. S., Walton, V., & Shulman, G. I. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381303 · Cited by 794
Cited by
Sorted by citations
Items 501–524 of 524
Thiazolidinediones, Adiponectin and Insulin Resistance
Chan, N. N., Mrcp, C., & Kong, A. P. S. (2005)
Hinweise auf Reduktion von Steatosis hepatis durch Metformin in vitro
Schramm, S. (2012) · Qucosa (Saxon State and University Library Dresden)
Kotronen, A., Juurinen, L., Tiikkainen, M., & Vehkavaara, S. (2008)
Obesity and metformin in pregnancy
Chiswick, C. A. (2017) · ERA
New pharmacological approaches in type 2 diabetes mellitus
Cusi, K. J. (2009) · Dialnet (Universidad de la Rioja) · doi:10.1016/b978-84-8086-683-5.50016-0
Metabolic effects of dipeptyl peptidase 4 inhibitor in type 2 diabetes
Macauley, M. (2016)
Pharmacological Options for NASH
Stern, C., & Ratziu, V. (2020) · Springer eBooks · doi:10.1007/978-3-319-95828-6_17
Research Progress of Metformin in the Treatment of Non-alcoholic Fatty Liver Disease
Liu, C., & Xie, J. (2020) · Advances in Bioscience and Bioengineering · doi:10.11648/j.abb.20200804.13
Al-Rubaie, B. J. U., Al-Mukhtar, N. J. H., & Al-Shemmary, B. D. (2011) · Medical Journal of Babylon
Mubeen, S., Rehan, R., Sundus, S., Raza, I., & Jabeen, S. (2019) · Journal of Bahria University Medical and Dental College · doi:10.51985/jbumdc2019072
Current literature in diabetes
(2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.565
Bulcão, C., Giuffrida, F. M. A., Ribeiro-Filho, F. F., & Ferreira, S. R. G. (2007) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2007000200009
Do Non Alcoholic Fatty Liver Disease Patients Have more Severe Metabolic Syndrome
Basit, A., Ali, M., Batool, M., Jakhrani, H. A. S., Aamer, A. X. A., & Naz, M. (2022) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs22169483
Metabolic-associated fatty liver disease: pharmacological management
Shi, Y., & Fan, J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-98368-6.00010-0
Study on the Correlation between Adiponectin and Its Gene Polymorphism and Diabetic Complications
焦, 怡. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.1361296
Weitzner, Z. N., Kim, K. H., Kim, Y., Seo, K. W., Choi, Y. S., & Dutson, E. (2023) · Surgical Endoscopy · doi:10.1007/s00464-023-10549-1
ADVANTAGES OF METFORMIN FOR A DIVERSITY OF DISEASES
Jaiswal, H., Panda, P. D., & Bharatia, R. (2023) · International Journal of Pharma Professional’s Research (IJPPR) · doi:10.48165/ijppronline.2023.14106
Low Hepatic CEACAM1 Tethers Metabolic Dysfunction Steatohepatitis to Atherosclerosis
Khoury, S. E., Harake, S. N. A., Youssef, T., Risk, C. E., Helou, N., Doumet, N. M., Aramouni, K., Azar, S. T., Najjar, S. M., & Ghadieh, H. E. (2025) · Livers · doi:10.3390/livers5030034
The effect of metformin-induced AMPK activation on adipogenesis and HIV replication
Alexandre, K. B. (2008) · University of the Witwatersrand, Johannesburg Institutional Repository on DSpace (University of the Witwatersrand, Johannesburg)
Marqueurs diagnostiques et pronostiques de la stéatohépatite métabolique
Coilly, A. (2019) · theses.fr (ABES) · doi:10.70675/488abf31z3acfz4f13z88e2zd974ef8b9b7b
Huang, Q., Liang, Z., Zeng, Y., Yao, C., He, J. S., Cao, Y., & Chen, Y. (2026) · Food Frontiers · doi:10.1002/fft2.70337
12 Niet-alcoholische steatohepatitis
Jansen, P. L. M. (2009) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-313-7437-3_12
Metadata
- Authors
- Tiikkainen, M., Häkkinen, A.-M., Korsheninnikova, E., Nyman, T., Mäkimattila, S., & Yki-Järvinen, H.
- Affiliations
- University of Helsinki (FI)
- Department of Medicine, Division of Oncology, University of Helsinki, Helsinki, Finland
- Minerva Foundation (FI)
- Department of Medicine, Division of Diabetes, University of Helsinki, Helsinki, Finland
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2004-08-01
- Volume
- 53
- Issue
- 8
- Pages
- 2169-2176
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2107068945
- Cited by
- 524
- References
- 48
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 6 · 2023: 8 · 2022: 6 · 2021: 14 · 2020: 16 · 2019: 6 · 2018: 15 · 2017: 12 · 2016: 18 · 2015: 19 · 2014: 24 · 2013: 26 · 2012: 15
- FWCI
- 34.05
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Suomen Lääketieteen Säätiö
- Biomedicum Helsinki-säätiö
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- rosiglitazone, metformin, type 2 diabetes, hepatic insulin resistance, hepatic insulin sensitivity, liver fat, insulin clearance, adiponectin, adipose tissue gene expression, PPARγ, lipoprotein lipase, insulin-stimulated glucose uptake, 1H NMR, drug comparison, weight loss, HbA1c
- MeSH terms
- Rosiglitazone, Adipose Tissue, Cholesterol, Diabetes Mellitus, Type 2, Female, Gene Expression Regulation, Humans, Hypoglycemic Agents, Insulin, Insulin Resistance, Liver, Male, Metformin, Middle Aged, Triglycerides, Thiazolidinediones, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
